Abstract
The in vitro activity of Schering 56592, a new azole drug, was compared with those of fluconazole and itraconazole against 103 isolates of Candida comprising 10 different species. Schering 56592 was more active than itraconazole and fluconazole, and it was active against many fluconazole-resistant isolates.
Full Text
The Full Text of this article is available as a PDF (124.5 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Baily G. G., Perry F. M., Denning D. W., Mandal B. K. Fluconazole-resistant candidosis in an HIV cohort. AIDS. 1994 Jun;8(6):787–792. doi: 10.1097/00002030-199406000-00010. [DOI] [PubMed] [Google Scholar]
- Denning D. W. Can we prevent azole resistance in fungi? Lancet. 1995 Aug 19;346(8973):454–455. doi: 10.1016/s0140-6736(95)91314-9. [DOI] [PubMed] [Google Scholar]
- Espinel-Ingroff A., Kish C. W., Jr, Kerkering T. M., Fromtling R. A., Bartizal K., Galgiani J. N., Villareal K., Pfaller M. A., Gerarden T., Rinaldi M. G. Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests. J Clin Microbiol. 1992 Dec;30(12):3138–3145. doi: 10.1128/jcm.30.12.3138-3145.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Galgiani J. N., Lewis M. L. In vitro studies of activities of the antifungal triazoles SCH56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts. Antimicrob Agents Chemother. 1997 Jan;41(1):180–183. doi: 10.1128/aac.41.1.180. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Johnson E. M., Davey K. G., Szekely A., Warnock D. W. Itraconazole susceptibilities of fluconazole susceptible and resistant isolates of five Candida species. J Antimicrob Chemother. 1995 Nov;36(5):787–793. doi: 10.1093/jac/36.5.787. [DOI] [PubMed] [Google Scholar]
- Johnson E. M., Warnock D. W., Luker J., Porter S. R., Scully C. Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis. J Antimicrob Chemother. 1995 Jan;35(1):103–114. doi: 10.1093/jac/35.1.103. [DOI] [PubMed] [Google Scholar]
- Law D., Moore C. B., Wardle H. M., Ganguli L. A., Keaney M. G., Denning D. W. High prevalence of antifungal resistance in Candida spp. from patients with AIDS. J Antimicrob Chemother. 1994 Nov;34(5):659–668. doi: 10.1093/jac/34.5.659. [DOI] [PubMed] [Google Scholar]
- Martinez-Suarez J. V., Rodriguez-Tudela J. L. Patterns of in vitro activity of itraconazole and imidazole antifungal agents against Candida albicans with decreased susceptibility to fluconazole from Spain. Antimicrob Agents Chemother. 1995 Jul;39(7):1512–1516. doi: 10.1128/aac.39.7.1512. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Perfect J. R., Cox G. M., Dodge R. K., Schell W. A. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. Antimicrob Agents Chemother. 1996 Aug;40(8):1910–1913. doi: 10.1128/aac.40.8.1910. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pfaller M. A., Messer S., Jones R. N. Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae. Antimicrob Agents Chemother. 1997 Feb;41(2):233–235. doi: 10.1128/aac.41.2.233. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rodriguez-Tudela J. L., Martinez-Suarez J. V. Improved medium for fluconazole susceptibility testing of Candida albicans. Antimicrob Agents Chemother. 1994 Jan;38(1):45–48. doi: 10.1128/aac.38.1.45. [DOI] [PMC free article] [PubMed] [Google Scholar]